You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Set Sail on the Antimicrobial StewardSHIP: Best Practices in Optimizing Infection Management

  • Authors: Kenneth A. Alexander, MD, PhD; Seth Koenig, MD; Trevor Van Schooneveld, MD
  • CME / ABIM MOC / CE Released: 5/19/2023
  • Valid for credit through: 5/19/2024
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)

    IPCE - 1.00 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for infectious disease (ID) specialists, critical care specialists, emergency medicine clinicians, primary care physicians, nurse practitioners (NPs), physician assistants (PAs), and pharmacists.

The goal of this activity is for learners to be better able to incorporate multiplex polymerase chain reaction (PCR) testing into the comprehensive management of patients with infectious diseases to improve antibiotic stewardship practices.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Burden of antimicrobial resistance
  • Have greater competence related to
    • Individualizing care strategies that incorporate the use of rapid PCR panels to mitigate potential consequences of antimicrobial resistance
  • Demonstrate greater confidence in their ability to
    • Collaborate with the healthcare team to facilitate the implementation of antimicrobial stewardship practices


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Kenneth A. Alexander, MD, PhD

    Division of Infectious Diseases
    Nemours Children's Hospital
    Professor of Clinical Sciences
    The University of Central Florida College of Medicine
    Orlando, Florida


    Kenneth A. Alexander, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Realta Pharmaceuticals
    Speaker or member of speakers bureau for: Merck & Co., Inc./Merck Sharpe & Dohme; Moderna, Inc.

  • Seth Koenig, MD

    Pulmonary and Critical Care
    Stony Brook University Hospital
    Stony Brook, New York


    Seth Koenig, MD, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Fujifilm SonoSite

  • Trevor Van Schooneveld, MD

    Division of Infectious Diseases
    Department of Internal Medicine
    University of Nebraska Medical Center
    Omaha, Nebraska


    Trevor Van Schooneveld, MD, has the following relevant financial relationships:
    Consultant or advisor for: bioMérieux SA
    Speaker or member of speakers bureau for: bioMérieux SA; Thermo Fisher Scientific Inc.
    Research funding from: AN2 Therapeutics; bioMérieux SA; Insmed Incorporated


  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC 


    Roderick Smith, MS, has no relevant financial relationships.

  • Kevan Chambers, FRSPH

    Medical Writer, Medscape, LLC


    Kevan Chambers, FRSPH, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-23-169-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Set Sail on the Antimicrobial StewardSHIP: Best Practices in Optimizing Infection Management

Authors: Kenneth A. Alexander, MD, PhD; Seth Koenig, MD; Trevor Van Schooneveld, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/19/2023

Valid for credit through: 5/19/2024



  1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629-655.
  2. Walsh TR. 'Antimicrobial resistance is a slow tsunami.' Health Europa. April 22, 2022. Accessed May 1, 2023.
  3. Saud B, et al. Methicillin-resistant and biofilm-producing Staphylococcus aureus in nasal carriage among health care workers and medical students. Can J Infect Dis Med Microbiol. 2023;2023:8424486.
  4. Dik JW, et al. Measuring the impact of antimicrobial stewardship programs. Expert Rev Anti Infect Ther. 2016;14:569-575.
  5. Gaieski DF, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med. 2010;38:1045-1053.
  6. Micek ST, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742-1748.
  7. Messacar K, et al. Implementation of rapid molecular infectious disease diagnostics: the role of diagnostic and antimicrobial stewardship. J Clin Microbiol. 2017;55:715-723.
  8. O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations: Review on Antimicrobial Resistance. Published May 2016. Accessed May 1, 2023.
  9. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Revised December 2019. Accessed May 1, 2023.
  10. Peleg AY, et al. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010;362:1804-1813.
  11. Dunne MW, et al. A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020. BMC Infect Dis. 2022;22:194.
  12. Critchley IA, et al. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019;14:e0220265.
  13. Mohanty S, et al. Trends in Streptococcus pneumoniae antimicrobial resistance in US children: a multicenter evaluation. Open Forum Infect Dis. 2023;10:ofad098.
  14. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
  15. Jones BE, et al. Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis. 2015;61:1403-1410.
  16. Zilberberg MD, et al. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019. Infect Control Hosp Epidemiol. 2022;43:277-283.
  17. Centers for Disease Control and Prevention (CDC). Increase in extensively drug-resistant shigellosis in the United States. CDC Health Alert Network. February 24, 2023. Accessed XXXX.
  18. Zilberberg MD, et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18:596.
  19. Costelloe C, et al. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ. 2010;340:c2096.
  20. Filice GA, et al. Diagnostic errors that lead to inappropriate antimicrobial use. Infect Control Hosp Epidemiol. 2015;36:949-956.
  21. Fernando SM, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med. 2020;46:1170-1179.
  22. Appaneal HJ, et al. Frequency and predictors of suboptimal prescribing among a cohort of older male residents with urinary tract infections. Clin Infect Dis. 2021;73:e2763-e2772.
  23. Weng QY, et al. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017;153:141-146.
  24. Curran J, et al. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect. 2022;28:479-490.
  25. de Jong E, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819-827.
  26. Kyriazopoulou E, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med. 2021;203:202-210.
  27. Banerjee R, et al. Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing. Clin Infect Dis. 2015;61:1071 -1080.
  28. Dien Bard J, et al. Panels and syndromic testing in clinical microbiology. Clin Lab Med. 2020;40:393-420.
  29. Choi JJ, et al. Impact of a multiplex polymerase chain reaction panel on duration of empiric antibiotic therapy in suspected bacterial meningitis. Open Forum Infect Dis. 2021;8:ofab467.
  30. Cybulski RJ Jr, et al. Clinical impact of a multiplex gastrointestinal polymerase chain reaction panel in patients with acute gastroenteritis. Clin Infect Dis. 2018;67:1688-1696.
  31. Timbrook TT, et al. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:15-23.
  32. Centers for Disease Control and Prevention (CDC). Core elements of hospital antibiotic stewardship programs. Updated April 28, 2021. Accessed May 1, 2023.
  33. Magill SS, et al. Assessment of the appropriateness of antimicrobial use in US hospitals. JAMA Netw Open. 2021;4:e212007.
  34. Centers for Disease Control and Prevention (CDC). Improving antibiotic use. 2023. Accessed May 1, 2023.
  35. Infectious Diseases Society of America (IDSA). Promoting antimicrobial stewardship in human medicine. 2023. Accessed May 1, 2023.
  36. Schwartz DN. Editorial commentary: antimicrobial stewardship in US hospitals: is the cup half-full yet? Clin Infect Dis. 2016;63:450-453.
  37. Deshpande A, et al. Intravenous to oral antibiotic switch therapy among patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2023:ciad196.
  38. Oxman D, et al. Incidence of multidrug resistant infections in emergency department patients with suspected sepsis. Am J Med Sci. 2020;360:650-655.
  39. Smieszek T, et al. Potential for reducing inappropriate antibiotic prescribing in English primary care. J Antimicrob Chemother 2018;73(suppl 2):ii36-ii43.
  40. Rahbi FA, et al. Physicians' attitudes, knowledge, and practices regarding antibiotic prescriptions. J Glob Antimicrob Resist. 2023;32:58-65.
  41. Schuts EC, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:847-856.
  42. Barlam TF, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51-e77.
  43. Gerber JS, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. JAMA. 2013;309:2345-2352.
  44. Poole S, et al. Rapid syndromic molecular testing in pneumonia: the current landscape and future potential. J Infect. 2020;80:1-7.
  45. DíazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control. 2012;40:526-529.
  46. Zetts RM, et al. Primary care physicians' attitudes and perceptions towards antibiotic resistance and outpatient antibiotic stewardship in the USA: a qualitative study. BMJ Open. 2020;10:e034983.
  47. National Heart Lung and Blood Institute (NHLBI). Bronchitis. Updated December 2, 2022. Accessed May 1, 2023.
  48. Schroeck JL, et al. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. Antimicrob Agents Chemother. 2015;59:3848-3852.
  49. Amar S, et al. Prevalence of common infectious diseases after COVID-19 vaccination and easing of pandemic restrictions in Israel. JAMA Netw Open. 2022;5:e2146175.
  50. Sydenham RV, et al. Prescribing antibiotics: the use of diagnostic tests in general practice. A register-based study. Scand J Prim Health Care. 2021;39:466-475.
  51. Sohn AJ, et al. Use of point-of-care tests (POCTs) by US primary care physicians. J Am Board Fam Med. 2016;29:371-376.
  52. Kalil AC, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61-e111.
  53. Buchan B, et al. Clinical evaluation and potential impact of a semi-quantitative multiplex molecular assay for the identification of pathogenic bacteria and viruses in lower respiratory specimens. Am J Respir Crit Care Med. 2018;197:A2617.
  54. Centers for Disease Control and Prevention (CDC). ESBL-Producing Enterobacterales in healthcare settings. Updated November 22, 2019. Accessed May 1, 2023.
  55. Cheng WL, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: appropriateness of empirical treatment matters. J Microbiol Immunol Infect. 2016;49:208-215.
  56. Shamsrizi P, et al. Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. BMJ Open. 2020;10:e030266.
  57. Paterson DL, et al. PRO: carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales. JAC Antimicrob Resist. 2021;3:dlab013.
  58. Ohnuma T, et al. Association of appropriate empirical antimicrobial therapy with in-hospital mortality in patients with bloodstream infections in the US. JAMA Netw Open. 2023;6:e2249353.
  59. Harbarth S, et al. Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2002;46:1619-1628.
  60. Lodise TP, et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36:1418-1423.
« Return to: Set Sail on the Antimicrobial StewardSHIP: Best Practices in Optimizing Infection Management
  • Print